不同类型的淋巴瘤发病年龄不同，如霍奇金淋巴瘤等在年轻和老年群体中均有可能发生，而慢性淋巴细 胞白血病(CLL，以下简称"慢淋")等是老年人比较多见，中位发病年龄在60岁及以上。 冯茹介绍："如果从严格的病理分类来说，淋巴瘤有百余个类型，还可以发生在身体的不同部位，比如 全身淋巴结、胃肠道、中枢神经系统、肺部、乳腺、睾丸等。除了指甲和头发以外，身体的其他部位均 有可能发生淋巴瘤。" 中新网广州1月1日电 (记者 蔡敏婕)"在老百姓的认知中，淋巴瘤听上去只是一种'瘤'，不像胃癌、肺癌 那样被明确称作'癌'，但事实上，淋巴瘤的本质是一种恶性肿瘤。"南方医科大学南方医院血液内科主 任医师冯茹在采访中表示，随着人口老龄化及体检意识提升，慢性淋巴细胞白血病检出率逐渐增高。 但是随着治疗时间的延长，许多中老年人随年龄增大，本身有合并心脏病、高血压等老年相关基础疾病 的风险增加，要着重考虑药物不良反应、耐受性及药物相互作用等问题。冯茹表示："希望未来能有更 多靶点清晰、副作用小的药物，让老年患者获益。" 慢淋这类疾病在这种慢病管理模式下，长期随访已成为全程管理中不可或缺的一部分。冯茹提醒，由于 淋巴瘤患者免疫功能较差，医生会 ...

初冬的宝鸡市老城区，街巷里透着几分萧瑟。走进宋治乾家的老房子，年过八旬的他正坐在客厅的 沙发上休息，手边放着布地格福吸入气雾剂，这是他对抗慢性阻塞性肺疾病的"日常武器"。自2022年确 诊并享受门诊慢特病待遇起，这瓶药就成了他生活中不可或缺的存在。 值得欣慰的是，从门诊慢特病报销额度的提高到报销流程的简化，从基层诊所药品配备的完善到健 康管理服务的提质，一系列惠民举措正切实为慢特病患者解忧。但我们也需清醒地认识到，慢特病保障 不仅需要政策的精准落地，更离不开政策的持续性发展。 健康中国战略强调"预防为主，防治结合"，这正与慢病管理的核心理念相契合。慢特病保障体系既 要筑牢后端的经济补偿防线，更要向前端的预防筛查延伸。比如，加大对年轻人的健康科普力度，让健 康生活理念深入人心；完善基层医疗机构的慢病筛查设备与能力，实现慢特病的早发现、早干预、早治 疗；推动医疗、医保、医药"三医"联动改革持续深化，降低药品价格、优化诊疗资源配置，让保障效能 最大化。 在这一过程中，商业保险可发挥重要补充与赋能作用，成为多层次医疗保障体系的关键力量。通 过"保险+健康管理"模式，商业保险公司可面向不同人群提供个性化健康科普、定期筛 ...

Core Viewpoint - The appointment of Dr. Charles Hugh-Jones as Global Chief Medical Officer of Fresenius Medical Care signals a shift in the dialysis and kidney care industry, where competition is moving from "equipment performance" to "medical systems and long-term efficacy management" [2]. Group 1: Fresenius Medical Care's Role - Fresenius Medical Care is not just a device manufacturer but provides a comprehensive life support system for chronic kidney disease patients, covering dialysis equipment, consumables, and service networks [3][4]. - The company's responsibilities extend beyond merely selling equipment to hospitals; it must maintain high stability in long-term safety, treatment consistency, and care quality [4]. Group 2: Transition from Maddux to Hugh-Jones - Dr. Franklin W. Maddux, who served as Global Chief Medical Officer since 2020, oversaw a period where the dialysis industry increasingly emphasized real-world evidence, long-term follow-up, and clinical quality management [5][7]. - Dr. Hugh-Jones brings a diverse background from Allergan, Pfizer, and Sanofi, aligning with a trend where chronic disease management is integrating broader medical strategies and data systems [9]. Group 3: Why "Medical Leadership" is Being Highlighted - The technological ceiling for dialysis devices is approaching, with differentiation increasingly based on long-term complication management, patient quality of life, and systemic care capabilities rather than single-treatment outcomes [11]. - Regulatory and payment systems are demanding clearer evidence of "clinical value," transforming the medical department from a compliance supporter to a builder of evidence systems [12]. - Data and services are reshaping the boundaries of device companies, pushing dialysis from "standardized device treatment" to "continuous medical services," necessitating deeper integration of medical decision-making into product and system design [13][14]. Group 4: Implications for the Medical Device Industry - The appointment of Hugh-Jones reflects a broader industry trend where medical functions are gaining strategic importance, especially in chronic disease management and long-term life support systems [15]. - Companies are increasingly recognizing that when product lifecycles span years, medical judgment becomes a critical component of product competitiveness [16].

12月22日，在格隆汇主办的"科技赋能·资本破局"线上分享会上，备受关注的"金格奖"年度卓越公司评 选结果正式揭晓。智云健康（09955.HK）凭借在战略转型、业务重构与可持续增长方面的突出表现， 荣获"年度转型先锋奖"。该奖项旨在表彰那些在动态变化的市场环境中，通过主动变革实现高质量发 展、创造长期价值，并对产业升级产生积极影响的领先企业。 智云健康的获奖，不仅是对其财务状况与战略执行力的肯定，更是对其以AI赋能慢病管理、以P2M（从 患者到工业）模式重塑行业价值链的转型路径的高度认可。 在AI医疗日益成为市场主线的今天，智云健康提供了一个鲜活案例：一家企业如何通过"做减法、聚主 业、强技术"，走出了一条良性增长与可持续转型之路。 | 2025年度卓越公司评选榜单 | | | --- | --- | | 公司名称 | 公司代码 | | 灿谷 | CANG.US | | 华兴资本控股 | 01911.HK | | 华赢集团 | AXG.US | | 汇通达网络 | 09878.HK | | 晋景新能 | 01783.HK | | 智云健康 名不力究院 | 09955.HK 56隆汇 | 战略聚焦与财务蜕变：转 ...

近日， 美敦力 （Medtronic） 宣布 ，其糖尿病业务单元 MiniMed Group 已正式向美国证券交易委员会 （SEC）提交首次公开募股（IPO）注册声明， 计划以独立公司身份登陆纳斯达克市场。若进展顺利，这将成 为美敦力近年来最重要的一次结构性资本调整。 从形式上看，这是一宗典型的 carve-out IPO；但若结合美敦力近几年的整体增长节奏、业务结构，以及资本市 场对不同类型医疗器械公司的估值偏好来看，这次分拆更像是一种 围绕增长曲线差异所做的主动重构 ，而非 简单的资产剥离或战略转向。 # 分 拆事件 时 间 线 回 顾 从目前披露的信息看，MiniMed 的独立上市并非一次性决策，而是经历了 逐步释放信号、阶段性推进 的过 程。回顾这一时间线，有助于理解此次 IPO 的背景与节奏。 2024 年初：首次释放"结构调整"信号 在 2024 财年相关财报电话会上， 美敦力 管理层首次明确提及，正在评估糖尿病业务在集团结构中的长期定 位，并强调该业务在商业模式、增长节奏与资本属性上，与集团其他高值器械板块存在显著差异。 2025 年初：MiniMed 向 SEC 提交 IPO 注册声明 最新披 ...

智通财经12月21日讯（编辑 笠晨）近年来A股上市公司分红意愿显著提升，市场分红生态持续优化，呈 现出分红总额、参与分红公司数量占比以及年内多次分红公司数量逐年递增的趋势。choice数据统计， 截至发稿，以股权登记日计算，今年以来A股上市公司现金分红总额达到2.61万亿元，已超过2024年全 年，创出历史新高。 Wind数据显示，今年以来，A股上市公司迈瑞医疗、三七互娱、御银股份和玲珑轮胎分红次数均为三 次。山东路桥、雅戈尔、深圳华强、奕帆传动、陕国投A、鱼跃医疗、行动教育、南山铝业、隆扬电 子、艾融软件、分众传媒、药明康德、百龙创园、吉比特、华宝股份、新坐标、龙佰集团、远翔新材、 华明装备、卓创资讯、九强生物、金帝股份、开普检测、西部证券、海希通讯、开能健康、金能科技、 金岭矿业、国光股份和吉电股份分红次数均为两次。具体情况如下图： | 证券简称 | 分红总额 | 分红次数 | Wind行业 | | --- | --- | --- | --- | | | (亿元) | | | | 三七互娱 | 13. 86 | 3 | 传媒 | | 玲珑轮胎 | 3.59 | 3 | 汽车与零配件 | | 迈瑞医疗 | ...

12月12日，2025（第三届）"央广财经年度对话"大型融媒活动在北京顺利举办。本届活动以"启航'十五 五'澎湃新动能"为主题，汇聚了众多专家学者、企业家及金融机构代表，共同围绕产业发展新路径展开 探索。 方舟云康打造的"AI+慢病管理"路径，不仅聚焦于技术层面的创新突破，更注重于可衡量、可复制的商 业价值与社会价值。企业创新推出的"熟人医患"服务模式，以患者首次线下面诊建立的信任为基础，通 过线上平台与AI工具的深度融合，为患者提供长期、持续的慢病管理服务，从而形成了高粘性、高复 购率的用户生态。2025年中期业绩充分印证了这一模式的强大生命力与用户认可度。数据显示，方舟云 康平台付费用户复购率高达85.4%。 在推动自身发展的同时，方舟云康积极践行产业协同，联动行业优质伙伴共同推动互联网医疗高质量发 展。今年，方舟云康与腾讯健康深化合作，联合发布了"AI+慢病管理"解决方案，推动我国慢病管理领 域迈入全新发展阶段。同时，企业还与旺山旺水、诺和诺德、信达生物等多家领先的生物制药企业达成 战略合作，共同打通慢病管理全链路服务体系，为行业智能化、合规化、高效化发展注入新动能。 政策指引发展方向，方舟云康以AI助 ...

据悉，老来健康作为深耕慢病管理的数字健康平台，已服务超3400万名用户，对接10个省医保门特慢病 监管服务系统，覆盖全国超2亿名老人。此次"肾小保"SaaS软件的成功研发，是老来健康在三医协同领 域的重要突破，未来公司将持续迭代技术与服务，为更多医疗机构提供合规、高效、智能的数字化管理 解决方案，助力我国慢病管理体系高质量发展。 "'肾小保'最核心的价值，在于通过SaaS架构打破了医保、医疗、患者之间的信息壁垒，构建起'政策引 导—临床实施—患者参与'的三医协同闭环。"邵阳市中心医院负责人表示，自2025年10月份项目启动以 来，该SaaS软件已成功纳管159名腹透患者，患者满意度大幅提升，医院肾脏病管理的资源配置效率和 诊疗质量实现双重突破，为慢病管理提供了可复制、可推广的实践样本。 业内人士认为，老来健康"肾小保"以SaaS模式落地三医协同，具备三大推广优势：一是轻量化部署，降 低医疗机构数字化转型成本；二是数据实时协同，实现医保、医疗、患者三方信息互通；三是模式可扩 展性强，未来可从肾脏病管理延伸至糖尿病、高血压等更多慢病领域。该模式的成功推广，将为"十五 五"期间医疗保障智能化升级提供重要支撑。 本报 ...

Core Viewpoint - The increasing prevalence of chronic diseases in China, driven by an aging population and changing lifestyles, has transformed these conditions from "medical events" to "everyday realities," highlighting a significant public health challenge [1][2]. Group 1: Current Challenges in Chronic Disease Management - Chronic disease prevention and control in China faces a "high incidence, high mortality, high economic burden" and "low screening, low treatment, low compliance" dilemma, with 91% of deaths attributed to chronic non-communicable diseases like cardiovascular diseases and diabetes [1]. - Despite ongoing efforts in chronic disease management, there is a growing disconnect between evolving patient needs and the resources allocated to address these needs, leading to a new set of challenges in chronic disease prevention and treatment [2]. Group 2: Clinical Insights and Treatment Gaps - Many patients with chronic diseases experience treatment failures, with over 85% of chronic disease patients exhibiting comorbid conditions, necessitating a shift towards integrated management approaches [3]. - The rising comorbidity rates among chronic diseases, such as the overlap between cardiovascular and respiratory diseases, underscore the need for comprehensive treatment strategies [3]. Group 3: Innovative Approaches by Pharmaceutical Companies - Pharmaceutical companies like AstraZeneca are focusing on breaking through treatment bottlenecks by developing innovative therapies and comprehensive treatment plans that address the interconnected nature of chronic diseases [4]. - AstraZeneca has presented over 80 studies at major international conferences, targeting cardiovascular, renal, metabolic, respiratory, and autoimmune diseases, aiming to provide new treatment insights and improve patient outcomes [4]. Group 4: Product Development and Pipeline - AstraZeneca's portfolio includes over 10 innovative drugs in the chronic disease sector, emphasizing a multi-faceted approach to managing common chronic conditions through a combination of single and combination therapies [5]. - The company plans to expand its offerings with over 40 new products and indications in various chronic disease areas, enhancing its treatment matrix from generic to specialty drugs [5]. Group 5: Collaborative and Technological Innovations - The establishment of a tiered healthcare system has expanded chronic disease management from hospitals to community and home settings, but challenges remain in addressing diverse patient needs and resource allocation [7]. - AstraZeneca is leveraging technology, such as AR-assisted lung function testing, to improve screening and treatment efficiency, thereby enhancing the management of respiratory diseases [8]. Group 6: Future Directions in Chronic Disease Management - The industry is undergoing a transformation from a disease-centered approach to a patient-centered model, emphasizing the importance of understanding and responding to unmet patient needs [9]. - The future competitiveness in chronic disease management will depend on the ability to innovate scientifically and collaboratively, creating new value propositions in the healthcare ecosystem [9].

Core Viewpoint - The increasing prevalence of chronic diseases in China, driven by an aging population and changing lifestyles, has led to a situation where chronic diseases are now a "normal part of life," creating significant health and economic burdens [1][2]. Group 1: Current Challenges in Chronic Disease Management - Chronic disease prevention and control in China faces a "high incidence, high mortality, high economic burden" and "low screening, low treatment, low compliance" dilemma, with 91% of total deaths attributed to chronic non-communicable diseases such as cardiovascular diseases, diabetes, and respiratory diseases [1]. - There is a growing demand for comprehensive management of chronic diseases, as patients experience co-morbidities and require integrated treatment approaches, yet investment in chronic disease management has decreased in recent years [2][3]. Group 2: Innovations in Treatment Approaches - AstraZeneca is focusing on breaking through the bottlenecks of single-point treatments by adopting a holistic view to address the interconnections between diseases, aiming to improve patient outcomes through innovative therapies and systematic treatment plans [4]. - The company has presented over 80 studies at major international conferences, covering cardiovascular, renal, metabolic, respiratory, and autoimmune treatment areas, providing new targets and ideas for clinical treatment [4]. Group 3: Future Directions and Strategic Initiatives - AstraZeneca plans to expand its product pipeline with over 40 new products and indications in chronic disease treatment, including areas such as amyloidosis, weight management, liver diseases, and systemic lupus erythematosus, creating a robust and diverse treatment matrix [8]. - The company is also enhancing grassroots diagnostic capabilities and leveraging technology, such as AR-assisted lung function testing, to improve screening rates and treatment efficiency for chronic respiratory diseases [10]. Group 4: Collaborative Models for Chronic Disease Management - The establishment of a graded diagnosis and treatment system is extending chronic disease management from hospitals to communities and homes, aiming for comprehensive coverage and improved management efficiency [9]. - AstraZeneca is promoting collaborative models, such as the "hospital-community linkage" approach, to provide standardized, integrated, and continuous chronic disease management services across various healthcare settings [9][10].